In this issue:
- Neoadjuvant durvalumab + chemotherapy for upper tract urothelial carcinoma
- Ipilimumab-nivolumab for non-clear cell RCC
- Safety and efficacy of ICIs in cardiac metastases
- Docetaxel ± pembrolizumab for metastatic castration resistant prostate cancer
- Avelumab first-line maintenance for advanced urothelial carcinoma
- Lymph node only metastatic urothelial carcinoma treated with gemcitabine-cisplatin ± nivolumab
- ICIs in patients with autoimmune neurological disorders
- Lenvatinib-pembrolizumab vs. sunitinib in advanced RCC: biomarker analyses
- ICIs in advanced urothelial carcinoma according to histological subtype
- Retifanlimab in advanced penile SCC
Please login below to download this issue (PDF)